Atopy in Dogs

MedVet Columbus is currently enrolling patients in a study evaluating the benefits and effectiveness of a new diet supporting dogs diagnosed with Canine Atopic Dermatitis (CAD).

Clinical Study Patient Eligibility

  • Dogs must be adults and weigh at least 5kgs/11 lbs.
  • Must be diagnosed with CAD by a Veterinary Dermatologist
  • Must be on routine flea prevention for at least 30 days from time of screening
  • Must have been on the same diet for at least five weeks prior to screening
  • May be on allergy vaccinations if they have been them for at least nine months
  • Have not been treated with any long-acting steroids for at least eight weeks
  • All medication for allergies must be stable for at least 30 days prior to screening
  • Dogs with food allergies (confirmed with an elimination diet trial) are excluded from the study
  • Cannot have or suspected to have a food hypersensitivity to poultry.
  • Cannot have significant health conditions (such as Cushing’s disease or chronic kidney disease) or be recently diagnosed with hypothyroidism (or other systemic diseases that may interfere with the outcomes)

Requirements of the Owner(s) of Study-eligible Patients

  • Must be able to return for four study visits at a frequency of every three weeks after the initial visit for a total of 12 weeks (visits are day 0, week 3, 6, 9, 12 for a total of 5 visits).
  • Must monitor the patient’s clinical signs throughout the 12 weeks and record findings in a diary
  • Must ensure that no other foods, including treats and human food, are fed during the study period
  • May be asked for pictures of their pet
  • Should not have known plans to move, renovate their home, or add additional pets during the study period

Study Information

Patients will be screened by one of our dermatologists to determine eligibility for enrollment. Enrolled patients can be fed either dry food only or a combination of dry and wet food. Treats may need to be discontinued for 12 weeks.

Client Savings

All study related visits (including lab work during the screening visit) and diet will be provided to the owner(s) at no cost to the owner(s).

Contacts

Drs. Natalie Theus or Elizabeth Toops at MedVet Columbus, 614.412.4402 or emailing derm.columbus@medvet.com.

Lymphoma Study in Dogs

MedVet Akron, MedVet Dallas, and MedVet Salt Lake City are currently enrolling patients in multicenter, fully funded clinical trial to evaluate the effectiveness and safety of verdinexor for the treatment of naïve or first relapse lymphoma in dogs.

Trial Eligibility:

  • We are enrolling canine patients meeting the following criteria:
  • At least one year old.
  • Weighs at least 19 pounds.
  • Confirmed diagnosis of lymphoma by cytology or biopsy.
  • Dog who has not received any treatment for lymphoma OR has failed a single round of any chemotherapy.
  • Has not received prior radiation and/or immunotherapy specifically for the treatment of lymphoma.
  • Is not participating in another study or is receiving an investigational therapy.
  • Is not lactating, pregnant, or intended for breeding.

*Other study inclusion and exclusion criteria apply. The MedVet Medical Oncologist will decide if your patient is a good candidate for this study after examination. *

Study Information:

The study is a “controlled” study, which means that some participants receive treatment and others receive a placebo. The treatment or placebo tablets are to be administered with food twice weekly for eight weeks.

This study is also “blinded” or “masked,” meaning that neither you nor the veterinarian making observations will know if your patient received the treatment.

Requirements:

Qualified patients and their owners should expect to stay in the study for 56 days and have six scheduled visits at the participating MedVet location. Clients will also be required to complete health questionnaires, report, and record abnormal daily observations and dosing using a phone app at home throughout the study.

If qualified, your patient would receive (at no cost to you or their owner):

  • Investigational medicine (verdinexor) or the placebo tablets.
  • Study-related examinations and tests.
  • Time with a veterinary specialist

We would be happy to provide you with additional information regarding the study. Please reach out to Dr. Bloch (MedVet Akron), Dr. McQuown (MedVet Dallas), or Dr. Wright (MedVet Salt Lake City).

Cats with Feline Chronic Gingivostomatitis

NOTICE: ENROLLMENT PAUSED

MedVet Indianapolis

Overview:

MedVet Indianapolis is currently enrolling cats with chronic gingivostomatitis that have not responded to standard treatment in a study to evaluate the safety and efficacy of a stem cell based therapy to treat cats with FCGS that have not had success with other treatments. This is a multi-site study based on research completed at UC Davis.

Qualifications to Enroll:

  • Cats must at least one year old and greater than or equal to 2kgs.
  • Cats must have documented diagnosis of FCGS and have undergone full standard of care therapy, full or pre-molar tooth extractions but are non-responsive for at least three to six months following extractions despite ongoing medical therapy.
  • Cats with co-morbidities are allowed as long as they will not interfere with treatment or evaluation of efficacy of the test article.
  • Owners must be able to return for all study visits over a 12-month period.
  • Cats may not have any planned surgical procedures for the duration of the study.
  • Cats must be free of anti-inflammatory and immunosuppressant therapy for 28 days prior to therapy and remain off those therapies during the trial. Cats can be on these therapies at the time of the first examination with the MedVet BOARD CERTIFIED VETERINARY DENTIST™.

Client Savings:

Lab work and the stem cell therapy will be provided to the owner at no charge.  The sponsor will also cover a significant portion of the administration costs.

Contact:

Indianapolis:

Edna Moore (Clinical Studies Coordinator) at edna.moore@medvet.com or 614.874.1271

Past Clinical Trials at MedVet Hospitals

The following trials are no longer accepting new patients:

  • Dogs With Protein Losing Enteropathy
  • Dogs with Dry Eye
  • Dogs With Osteosarcoma
  • Large Dogs Requiring Ruptured Cranial Cruciate Ligament Repair
  • Cats with Diabetes Mellitus
  • Small dogs requiring ruptured cranial cruciate ligament repair
  • Dogs with pruritus
  • Dogs with osteoarthritis
  • Large dogs requiring ruptured cranial cruciate ligament repair
  • Dogs with congestive heart failure (4 completed studies)
  • Dogs with t-cell lymphoma
  • Dogs with congestive heart failure (multi-site study)
  • Dogs with mast cell tumors
  • Dogs with diabetes mellitus (2 completed studies)
  • Dogs with hip dysplasia
  • Dogs requiring cranial cruciate or luxating patella repair surgery (post-operative pain study)
  • Dogs with ruptured cranial cruciate ligaments
  • Dogs with melanoma, osteosarcoma, soft tissue sarcoma, and squamous cell carcinoma
  • Cats with congestive heart failure
  • Dogs with nasal carcinoma
  • Cats with oral squamous cell carcinoma
  • Dogs with atopic disease
  • Dogs with epilepsy
  • Dogs with lymphoma
  • Dogs with Glioma
  • Dogs With Lens Changes
  • Dogs in Need of an Amputation

Contact Us

If you have a pet that you believe may qualify for a clinical study, please contact your primary care veterinarian and they can work with us to determine if a clinical trial is the best option for your pet. If you are a veterinarian with a patient that you believe could benefit from a clinical study, please contact us.

MedVet Clinical Trials

614.874.1271

clinical.studies@medvetforpets.com

If you would like to learn more about MedVet’s Clinical Studies Center or how you can collaborate with one of the clinical investigative teams at MedVet, click here.